Follicular lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 27
• CD20 14
• BTK 9
• BCL-2 5
• CD22 5
• MYC 3
• EZH2 2
• PD-1 3
• PI3K 0
• PD-L1 1
• TP53 0
• CD40 0
• CD47 0
• CXCR4 0
• EGFR 0
• HDAC 0
• ABL1 0
• AKT 0
• ALK 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD30 0
• CSF1R 1
• G6PD 0
• IL-1 0
• IL-15 0
• IL-17 0
• LAG-3 0
• MEK 0
• PPAR 0
• STAT3 0
• TFEB 0
• TIGIT 1
• TIM-3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 38+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

  NCT07098364· Fred Hutchinson Cancer Center· Updated 11 Sept 2026

  “Insufficient funding”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  NCT06256484· Atara Biotherapeutics· Updated 11 Mar 2026

  “Financial reasons”Registry text, quoted unchanged. Source

• Terminated

  A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

  NCT05336409· Century Therapeutics, Inc.· Updated 18 Dec 2025

  “Strategic decision”Registry text, quoted unchanged. Source

• Terminated

  Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT06343376· Roswell Park Cancer Institute· Updated 3 Aug 2025

  “Manufacturing issues”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

  NCT06026319· Marcela V. Maus, M.D.,Ph.D.· Source

• A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

  NCT04594642· AstraZeneca· Source

• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

  NCT04464200· Memorial Sloan Kettering Cancer Center· Source

• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

  NCT06045910· Cancer Research UK· Source

• ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

  NCT04049513· Malaghan Institute of Medical Research· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Whole Genome Sequencing 1
• Flow Cytometry 2
• Immunohistochemistry 12
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 2
• Cohort Studies 6
• Genome-Wide Association Study 4

• 18F-FDG PET/CT-based radiomics for differentiating low-grade and grade 3A of follicular lymphoma.

  BMC Med Imaging, Mar 2026

• Cell-free chromatin state tracing reveals disease origin and therapy responses.

  Nature, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.